Treatment

Bone Marrow Biopsy clinical trials

5 indexed studies · 1 currently recruiting

Active not recruitingPHASE2
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
This study looks at a new drug, enasidenib, for children and young people (aged 2-21) with a type of blood cancer called Acute Myeloid Leukemia (AML) that has come back or is hard to treat. It focuses on those with a specific genetic change in their cancer cells.
For: Recurrent Acute Myeloid Leukemia · Refractory Acute Myeloid Leukemia
United States · Canada
Active not recruitingPHASE2
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
This study is testing different combinations of new drugs (olaparib, durvalumab, capivasertib, and cediranib) for recurrent or hard-to-treat womb cancer. The aim is to find out if these combinations can stop the cancer from growing or spreading more effectively.
For: Endometrial Adenocarcinoma · Endometrial Mixed Cell Adenocarcinoma · Endometrial Serous Adenocarcinoma
United States · Canada
RecruitingPHASE2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
This study helps doctors find the best treatments for people with certain blood cancers like leukaemia. It uses special tests on blood and bone marrow to match patients with personalised treatments or standard care, aiming to improve how cancer treatments are chosen.
For: Acute Myeloid Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · Acute Myeloid Leukemia Post Cytotoxic Therapy
United States · Canada · Puerto Rico
Active not recruitingPHASE3
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
This study looks at new ways to treat a type of cancer called rhabdomyosarcoma, which can be aggressive. We're testing if adding a drug called vinorelbine to standard treatment, and then using a 'maintenance' therapy, helps stop the cancer from coming back.
For: Alveolar Rhabdomyosarcoma · Botryoid-Type Embryonal Rhabdomyosarcoma · Embryonal Rhabdomyosarcoma
United States · Australia · Canada
Active not recruitingPHASE2
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
This study looks at combining existing treatments for high-risk neuroblastoma to see if it works better. It's for children and young people who have already had intensive therapy, to help prevent the cancer from coming back.
For: Ganglioneuroblastoma, Nodular · Neuroblastoma
United States · Australia · Canada

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)